You are here : Home > Institutional Funds

Institutional Funds

Published on 25 April 2017
The main representative keywords of themes on which the Institute is positioned to compete for funding are: aging, AIDS, antimicrobial resistance, in vitro diagnostics, brain, cancer, immunity, nanosciences, personalized medicine, epigenetics, bioinformatics, rare diseases, bioenergy (photosynthesis, microalgae, biohydrogen).


Involvement of the institute in European programs

Below are listed all the projects of the 7th European Framework Program (FP7) of which the institute is a partner or even a coordinator. 3 great areas are affected: health, biotechnology and nanoscience.




Using current best practice against biotoxins, the EuroBioTox core members will develop and validate improved analytical tools, reagents and standard operating procedures based on realistic incident scenarios. Certified Reference Materials will be developed against this threat and, by establishing a European repository, will be made available to the EuroBioTox network including more than 50 European organisations.


PEVIA consortium aims to develop a new generation of vaccines against multiple Ebola virus strains, easy to produce and to deploy in the endemic regions. This will improve vaccine efficacy against various strains of a mutating virus to give a long lasting protection against multiple exposures to Ebola virus. In addition, our vaccine will not require storage at low temperatures (+4 to +8°C), overcoming the problems of stability, and storage in endemic regions, and allowing for ready deployment in the field.


ABACUS aims at a business-oriented and technology-driven development of a new algal biorefinery, thereby bringing to the market innovative algae-based ingredients for high-end applications, spanning from algal terpenes for fragrances to long-chain terpenoids (carotenoids) for nutraceuticals and cosmetic actives. 



The project SUPER-RESOL aims at preparing the commercialization of a new, simple, and cheap, way of extracting super-resolution from images obtained with classical confocal fluorescence microscopy.


ZIKAlliance, a multinational and multi-disciplinary research consortium will investigate clinical, fundamental, environmental and social aspects of ZIKV infection. In particular, ZIKAlliance will focus on the impact of ZIKV infection during pregnancy and the natural history of ZIKV in humans and their environment. In collaboration with two other EC funded consortia (ZikaPLAN and ZIKAction), ZIKAlliance will also work on the development of a preparedness platform in Latin America and the Caribbean.


DiamESTar aims to evaluate the Targeted delivery of therapeutic siRNA to Ewing sarcoma junction oncogene by traceable diamond nanocrystal – antibody fragment conjugate 


SE2B (Solar Energy into Biomass), will train 16 young researchers to work at the forefront of innovations that shape the bio-based economy. This ITN will focus on uncovering how the light reactions of photosynthesis are regulated, and on using this knowledge for a targeted optimization of the light use efficiency.​

ISOTOPICS, that we coordinate, is a European ITN project, aiming at training fifteen young researchers as experts in isotopic labeling. The development of new methods enabling a simple, fast and specific introduction of several labeling molecules is crucial for the pharma industry, strongly implied in this consortium. This strategic competence make possible a more efficient identification of drug candidates.


VENOMICS, that we are coordinating, is a European project which aims to discover innovative therapeutic molecules from the exploration of the diversity of animal venoms.


The FAST (Food Allergy Specific Therapy) project aims to develop a safe and effective treatment against food allergies, especially fish and fruit.

NANOGENOTOX aims to facilitate the safety assessment (safety) of manufactured nanomaterials by characterizing their potential genotoxic hazard.


EURATRANS ia rat-related functional genomics project across Europe for translational research.


LIVIMODE is a research consortium developing imaging agents to investigate the molecular origins of a disease.

The PERMED coordinating action and support on personalized medicine has been launched to coordinate efforts between European key stakeholders, to promote synergies and avoid duplication or competition to ensure maximum transparency and openness and prepare Europe to be at the forefront of global research in this area.


CHAARM stands for "Combined Highly Active Anti-Retroviral Microbicides." In other words, the project aims to develop new microbicides combinations that can be applied locally to reduce HIV transmission during sex.

KINDRED aims to create a unique and powerful discovery trypanosomatid anti-drugs (parasitic diseases) platform carried by the lab for the clinic.


SOLARH2 brings together 12 European laboratories worldwide for developing new ways of producing solar fuel, in this case hydrogen from abundant and truly inexhaustible resources such as water and solar energy.

"Genetically modified" cell factories (Code-engineered new-to-kind) for an innovative bio-production and enhanced security.


The challenges of the looming climate change and food security require new knowledge about the way stress impacts the quality of seeds as well as a re-evaluation of optimal storage conditions. EcoSeed addresses these challenges by bringing together a group of Europeans experts recognized in seed and converging sciences to characterize the quality of seeds and resilience to disturbance.


HARVEST (Marie Curie network formation ITN) of the light to harvest or the efficiency control of light utilization in plants and algae.


Designing new nanomedicines taken orally: Transporting therapeutic macromolecules across the intestinal barrier.

Nanomedicine for targeted imaging and treatment of atherothrombosis: development and initial clinical feasibility.

NANOMILE the project aims to establish a fundamental understanding of the interaction mechanisms between nanomaterials and living systems environment throughout the nanomaterials life cycle and a wide range of targets. The project will identify critical properties (physicochemical descriptors) that confer the ability to induce damage in the biological system, an important point to consider in the production of nanomaterials ('security by design').


The ERC TERNANOMED project aims to develop nanoterpenoids based assemblies to improve the treatment of serious diseases such as cancer and metabolic and infectious diseases.


BIOCHEMLIG (Marie Curie Actions, ITN): This project describes new approaches for the discovery of biocompatible and chemically specific ligation reactions. The goal is to develop new ligation methods with high efficiency, wide scope, high chemical selectivity and high yields.


IBITECS also coordinates a work package within the ABIRISK project (Innovative Medicine Initiative IMI) prediction and analysis of immunogenicity of biopharmaceuticals (therapeutic proteins and antibodies).

For information on European Affairs of the CEA's Fundamental Research Division see Section Europe DFS .

Major international collaborations outside Europe

The teams of the institute maintain more than 150 international collaborations with leading research laboratories in the following countries: United States, Brazil, India, Canada, Japan ...
For example, a delegation of experts from DSV conducted by its director, Gilles Bloch, participated in 2014 in Sao Paulo, to the workshop "Toxinology and Vaccines" organized jointly with the Butantan Institute (IBU) and the Faculty of Medicine of the University of Sao Paulo (USP). The IBU is a leading health and research actor in Brazil that provides a 90% share of Brazilian production of vaccines and anti-venoms and on the other hand, developing important research in the study and medical use of toxins.
The IBITECS researchers, specialists in these fields, made the trip and the meeting ended with the signing of a Memorandum of Understanding (MoU) illustrating the will of Franco-Brazilian actors to structure their relationship in the long term.



©Butantan Institute

For more information on DRF international collaborations consult our dedicated pages.